Roman G. Rubio, MD, has joined Revance Therapeutics as the biotechnology company’s senior vice president of clinical development. Dr. Rubio will lead Revance’s clinical development team, focusing on further advancing its neurotoxin development programs.Prior to Revance, Dr. Rubio was senior vice president of translational medicine at Avalanche Biotechnologies, and he served more than 11 years at Genentech.
“Dr. Rubio played key leadership roles in the successful development and approval of several ophthalmic indications for Genentech’s Lucentis (ranibizumab injection) and has led teams that managed line extensions, created market strategies, and generated disease and product education initiatives,” said Dan Browne, president and CEO of Revance. “Dr. Rubio is a published investigator with extensive biologic drug development experience managing early- and late-stage product development, clinical development, medical affairs, and physician relations. We are pleased to add a seasoned drug developer with a proven track record for all phases of product development to our senior management team.”
